Sun Pharma down on concerns about USFDA observations on Dadra unit

Last Updated: Fri, Apr 21, 2017 12:10 hrs
Sun Pharma

Sun Pharmaceutical Industries Limited shares are trading weak today on reports the company's Dadra unit has received 11 observations from USFDA.

At Rs 643,50, off the day's low of Rs 638.75, the stock is now down nearly 2% from its previous closing price.

According to reports in some sections of the media, the US drug regulator Food & Drug Administration has found lab records at Sun Pharmaceutical Industries' Dadra plant to be incomplete. Among the observations issued by USFDA are the failure of the company to produce appropriate master or control record for each batch of drugs and failure to properly investigate batches which were not in compliance with specifications.



The regulator inspected the Dadra plant of the pharma major in the first week of this month. The Dadra site is Sun Pharma's biggest unit after the plant at Halol.

More from Sify: